In8bio, Inc. reported results
SEC 8-KRead source ↗
In8bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$0.3
Forward price-to-sales vs peers
Base case. Range ~$0.3–$1.3. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
In8bio, Inc. valuation: adjust assumptions and compare models →
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 33% in the quarter to 2026-06-30, the 4th beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
Things to watch
- Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 87% and a beta of 1.5 against the S&P 500.
Latest results
- Earnings per share
- -$0.25 against an average estimate of -$0.37: beat by 33.0%
- Share reaction
- -1.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Price chart
- 1 day+9.9%
- 1 week+4.2%
- 1 month-28.6%
- This year-61.1%
- 1 year-46.8%
- 5 years-99.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 6, 2026
- Next results (est.)
- November 5, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
Valuation models
We value In8bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.2 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.3 ~$0.4–$1.3 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$0.3 ~$0.3–$1.3 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare In8bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.11 | +75% | — | 0% |
| Next | −$0.95 | +15% | $1m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −10.4% on 90 days ago. In the last 30 days, 2 analysts raised In8bio, Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.24 | −$1.06 |
| 60 days ago | −$1.24 | −$1.06 |
| 30 days ago | −$1.09 | −$0.96 |
| 7 days ago | −$1.09 | −$0.96 |
| Now | −$1.11 | −$0.95 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.37 | −$0.25 | +33.0% |
| Mar 2026 | −$0.69 | −$0.26 | +62.3% |
| Dec 2025 | −$0.47 | −$0.45 | +5.3% |
| Sept 2025 | −$1.25 | −$0.85 | +31.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 0.4% of tradable shares
- Days to cover
- 0.64 at average volume
- Short interest, 1 month
- −48% to October 15, 2026
- Held by institutions
- 38% of shares
- Held by insiders
- 7.6% of shares
- Employees
- 18 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| INAB | −47% | −40% | −81% | −70% | −61% |
| Industry peers (median) | −57% | −17% | −28% | −5% | −26% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| INAB | 42% | 25% | 33% | 50% | 36% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| INAB | −70% | −79% | −87% | −88% | −65% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since July 30, 2021: 100% from July 30, 2021 to October 30, 2026. Getting back needed a 33196% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.90 – $2.59
- From 52-week high
- −64.9%
- vs 50-day average
- −20.5%
- vs 200-day average
- −37.1%
- Volatility (1 year)
- 87%
- Beta vs S&P 500
- 1.48
Share price after results
- Next day
- 2 up, 10 down typical move ±4.2%
- After a week
- 5 up, 7 down typical move ±8.3%
- After a month
- 5 up, 7 down typical move ±22.1%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | −1.0% | +0.5% | +19.3% | +21.3% |
| May 7, 2026 | 0.0% | +0.5% | +0.6% | −8.9% |
| March 12, 2026 | −5.0% | −2.1% | −13.6% | −32.2% |
| November 6, 2025 | −4.9% | −1.0% | +0.6% | +9.2% |
| August 7, 2025 | +10.0% | +0.7% | +14.3% | +2.9% |
| May 7, 2025 | +2.4% | +1.1% | −10.4% | −15.2% |
| March 13, 2025 | −9.6% | +0.7% | −6.4% | −39.0% |
| November 12, 2024 | −4.5% | −0.3% | −4.5% | −12.3% |
| August 8, 2024 | −1.4% | +2.8% | −15.0% | −57.0% |
| May 9, 2024 | 0.0% | +0.7% | +1.0% | +29.7% |
| March 14, 2024 | −8.8% | −0.9% | 0.0% | −18.4% |
| November 9, 2023 | −2.8% | +0.8% | −13.9% | +19.6% |
Fundamentals
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
- August 6, 2026
- May 7, 2026
- March 12, 2026
- November 6, 2025
- August 7, 2025
- May 7, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
In8bio, Inc. in brief
- What does In8bio, Inc. do?
- In8bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is In8bio, Inc.'s stock ticker?
- In8bio, Inc. trades under the ticker INAB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- When is In8bio, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — In8bio, Inc. announces its own schedule.
Follow research on In8bio, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.